US FDA Gives Approval for First Corneal Implantable Device
Published By : 17 Apr 2015 | Published By : QYRESEARCH
The United States Food and Drug Administration (US FDA) on Friday gave its approval for the KAMRA inlay, which is the first of its kind implantable device used to correct near vision in those patients who have not undergone a cataract surgery. The KAMRA inlay is implanted in the cornea - the clear, front surface - of one eye to improve near vision in patients suffering from presbyopia.
Presbyopia refers to the loss of ability an individual to change the power of focusing of the eye. This is a condition that comes with normal and natural aging and the consequent is difficulty with near vision. Individuals most likely to be affected by this condition are adults between the ages 40 and 50. The KAMRA inlay is a ring shaped device, which is opaque, and is intended to be used in patients between the ages 45 and 60. These patients have not had cataract surgery and are not able to focus on near objects or small print clearly. These patients need reading glasses with dioptres of power ranging from +1.00 to +2.50. These patients, however, do not require glasses or even contact lenses for clear distance vision.
William Maisel M D, who is the deputy center director for science at the Center for Devices and Radiological Health in the US FDA, states that presbyopia is a very natural process that comes with aging and this condition can make performing close-up work and tasks such as reading quite difficult. He also added that the KAMRA inlay offers patients a new alternative that corrects near vision in certain cases.
The KAMRA inlay implantable device blocks unfocused light rays from entering the eye and improves near vision. The device obstructs peripheral light rays at the same time allowing central light rays to penetrate through a tiny opening right in the center of the implanted device. This makes near objects as well as small print less hazy.